Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors

References

• Leder K, Weller PF. Microsporidiosis. In: UpToDATE. Rose BD (Ed.). UpToDate, MA, USA (2007).
   Google Scholar
• Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc. Natl Acad. Sci.95(26), 15183–15188 (1998).
   PubMedGoogle Scholar
• Wernert N, Stanjek A, Kiriakidis S et al. Inhibition of angiogenesis in vivo by ets-1 antisense oligonucleotides-inhibition of Ets-1 transcription factor expression by the antibiotic fumagillin. Angew. Chem. Int. Ed. Engl.28(21), 3228–3231 (1999).
   Google Scholar
• Little RF, Wyvill KM, Pluda JM et al. Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J. Clin. Oncol.18(13), 2593–2602 (2000).
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi’s sarcoma: an AIDS Malignancy Consortium Study. J. Clin. Oncol.24(9), 1389–1394 (2006).
   PubMed Web of Science ®Google Scholar
• Koon HB, Bubley GJ, Pantanowitz L et al. Imatinib-induced regression of AIDS-related Kaposi’s sarcoma. J. Clin. Oncol.23(5), 982–989 (2005).
   PubMed Web of Science ®Google Scholar
• Little RF, Pluda JM, Wyvill KM et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood107(12), 4650–4657 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang P, Nicholson DE, Bujnicki JM et al. Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis. J. Biomed. Sci.9(1), 34–40 (2002).
   PubMedGoogle Scholar
• Satchi-Fainaro R, Mamluk R, Wang L et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate caplostatin. Cancer Cell7, 251–261 (2005).
   PubMed Web of Science ®Google Scholar
• Watanabe N, Nishihara Y, Yamaguchi T et al. Fumagillin suppresses HIV-1 infection of macrophages through the inhibition of Vpr activity. FEBS580(11), 2598–2602 (2006).
   PubMedGoogle Scholar
• Okrój M, Kamysz W, Slominska EM, Mysliwski A, Bigda J. A novel mechanism of action of the fumagillin analog, TNP-470, in the B16F10 murine melanoma cell line. Anticancer Drugs16(8), 817–823 (2005).
   PubMedGoogle Scholar
• Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science282(5392), 1324–1327 (1998).
   PubMed Web of Science ®Google Scholar
• Molina JM, Goguel J, Sarfati C et al. Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. ANRS 054 Study Group. Agence Nationale de Recherche sur le SIDA. AIDS14(10), 1341–1348 (2000).
   PubMedGoogle Scholar
• Ingber D, Fujita T, Kishimoto S et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature348(6301), 555–557 (1990).
   PubMed Web of Science ®Google Scholar
• Placidi L, Cretton-Scott E, de Sousa G, Rahmani R, Placidi M, Sommadossi JP. Disposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res.55, 3036–3042 (1995).
   PubMed Web of Science ®Google Scholar
• Didier PJ, Phillips JN, Kuebler DJ et al. Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives in vitro and in vivo. Antimicrob. Agents Chemother.50(6), 2146–2155 (2006).
   PubMed Web of Science ®Google Scholar
• Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis1, 23–25 (1997).
   PubMedGoogle Scholar
• Molina JM, Tourneur M, Sarfati C et al.; Agence Nationale de Recherches sur le SIDA 090 Study Group. Fumagillin treatment of intestinal microsporidiosis. N. Engl. J. Med.346(25), 1963–1969 (2002).
   PubMed Web of Science ®Google Scholar
• Mohindra AR, Lee MW, Visvesvara G et al. Disseminated microsporidiosis in a renal transplant recipient. Transplant Infect. Dis.4, 102–107 (2002).
   PubMedGoogle Scholar
• Diesenhouse MC, Wilson LA, Corrent GF, Visvesvara GS, Grossniklaus HE, Bryan RT. Treatment of microsporidial keratoconjunctivitis with topical fumagillin. Am. J. Ophthalmol.115(3), 293–298 (1993).
   PubMedGoogle Scholar
• Folkman J. Angiogenesis. Ann. Rev. Med.57, 1–18 (2006).
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Von Roenn JH, Holden-Wiltse J et al. Fumagillin analog in the treatment of Kaposi’s sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J. Clin. Oncol.16(4), 1444–1449 (1998).
   PubMed Web of Science ®Google Scholar
• Bhargava P, Marshall JL, Rizvi N et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res.5(8), 1989–1995 (1999).
   PubMed Web of Science ®Google Scholar
• Cernaianu G, Frank S, Erbstösser K et al. TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model. Int. J. Colorectal Dis.21(2), 143–154 (2006).
   PubMedGoogle Scholar
• Perry BN, Govindarajan B, Bhandarkar SS et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J. Invest. Dermatol.126(10), 2316–2322 (2006).
   PubMed Web of Science ®Google Scholar